Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Certolizumab Pegol Drug Studies Find No New Safety Issues

  |  Issue: March 2015  |  

Zohydro ER is indicated for managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2015;74(1):96–103.
  2. Alder Biopharmaceuticals. Pipeline. Feb. 2, 2015. http://www.alderbio.com/therapeutics/pipeline.
  3. Mease P, Gottlieb AB, Berman A, et al. A Phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-il-6 monoclonal antibody, in adults with active psoriatic arthritis. Arthritis Rheumatol. 2014;66(11):Suppl. Abstract 952.
  4. Zogenix receives FDA approval of new formulation of Zohydro ER. First Word Pharma. 2015 Feb 1. http://www.firstwordpharma.com/print/1261369?tsid=17.

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    WindNight / shutterstock.com

    Why & How Our Biologic Drug Discussion with Patients Should Evolve

    As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…